Marieke E M van der Noordaa1, Ileana Ioan2, Emiel J Rutgers3,4, Erik van Werkhoven5, Claudette E Loo6, Rosie Voorthuis3, Jelle Wesseling7, Japke van Urk6, Terry Wiersma8, Vincent Dezentje9, Marie-Jeanne T F D Vrancken Peeters3,4, Frederieke H van Duijnhoven3. 1. Department of Surgical Oncology, NKI-AVL, Amsterdam, The Netherlands. m.vd.noordaa@nki.nl. 2. Department of Radiology, Policlinico San Donato, Milan, Italy. 3. Department of Surgical Oncology, NKI-AVL, Amsterdam, The Netherlands. 4. Department of Surgery, University of Amsterdam, Amsterdam, The Netherlands. 5. Department of Biometrics, NKI-AVL, Amsterdam, The Netherlands. 6. Department of Radiology, NKI-AVL, Amsterdam, The Netherlands. 7. Department of Pathology, NKI-AvL and Leiden University Medical Center, Amsterdam, The Netherlands. 8. Department of Radiation Oncology, NKI-AVL, Amsterdam, The Netherlands. 9. Department of Medical Oncology, NKI-AVL, Amsterdam, The Netherlands.
Abstract
BACKGROUND: Many cT3 breast cancer patients are treated with mastectomy, regardless of response to neoadjuvant systemic therapy (NST). We evaluated local control of cT3 patients undergoing breast-conserving therapy (BCT) based on magnetic resonance imaging (MRI) evaluation post-NST. In addition, we analyzed predictive characteristics for positive margins after breast-conserving surgery (BCS). METHODS: All cT3 breast cancer patients who underwent BCS after NST between 2002 and 2015 at the Netherlands Cancer Institute were included. Local recurrence-free interval (LRFI) was estimated using the Kaplan-Meier method, and predictors for positive margins were analyzed using univariable analysis and multivariable logistic regression. RESULTS: Of 114 patients undergoing BCS post-NST, 75 had negative margins, 16 had focally positive margins, and 23 had positive margins. Of those with (focally) positive margins, 12 underwent radiotherapy, 6 underwent re-excision, and 21 underwent mastectomy. Finally, 93/114 patients were treated with BCT (82%), with an LRFI of 95.9% (95% confidence interval [CI] 91.5-100%) after a median follow-up of 7 years. Predictors for positive margins in univariable analysis were hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) subtype, lobular carcinoma, and non-mass enhancement (NME) on pre-NST MRI. MRI response was not correlated to positive margins. In multivariable regression, the odds of positive margins were decreased in patients with HER2-positive (HER2+; odds ratio [OR] 0.27, 95% CI 0.10-0.73; p = 0.01) and TN tumors (OR 0.17, 95% CI 0.03-0.82; p = 0.028). A trend toward positive margins was observed in patients with NME (OR 2.38, 95% CI 0.98-5.77; p = 0.055). CONCLUSION: BCT could be performed in 82% of cT3 patients in whom BCT appeared feasible on post-NST MRI. Local control in these patients was excellent. In those patients with HR+/HER2- tumors, NME on MRI, or invasive lobular carcinoma, the risk of positive margins should be considered preoperatively.
BACKGROUND: Many cT3breast cancerpatients are treated with mastectomy, regardless of response to neoadjuvant systemic therapy (NST). We evaluated local control of cT3patients undergoing breast-conserving therapy (BCT) based on magnetic resonance imaging (MRI) evaluation post-NST. In addition, we analyzed predictive characteristics for positive margins after breast-conserving surgery (BCS). METHODS: All cT3breast cancerpatients who underwent BCS after NST between 2002 and 2015 at the Netherlands Cancer Institute were included. Local recurrence-free interval (LRFI) was estimated using the Kaplan-Meier method, and predictors for positive margins were analyzed using univariable analysis and multivariable logistic regression. RESULTS: Of 114 patients undergoing BCS post-NST, 75 had negative margins, 16 had focally positive margins, and 23 had positive margins. Of those with (focally) positive margins, 12 underwent radiotherapy, 6 underwent re-excision, and 21 underwent mastectomy. Finally, 93/114 patients were treated with BCT (82%), with an LRFI of 95.9% (95% confidence interval [CI] 91.5-100%) after a median follow-up of 7 years. Predictors for positive margins in univariable analysis were hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) subtype, lobular carcinoma, and non-mass enhancement (NME) on pre-NST MRI. MRI response was not correlated to positive margins. In multivariable regression, the odds of positive margins were decreased in patients with HER2-positive (HER2+; odds ratio [OR] 0.27, 95% CI 0.10-0.73; p = 0.01) and TN tumors (OR 0.17, 95% CI 0.03-0.82; p = 0.028). A trend toward positive margins was observed in patients with NME (OR 2.38, 95% CI 0.98-5.77; p = 0.055). CONCLUSION: BCT could be performed in 82% of cT3patients in whom BCT appeared feasible on post-NST MRI. Local control in these patients was excellent. In those patients with HR+/HER2- tumors, NME on MRI, or invasive lobular carcinoma, the risk of positive margins should be considered preoperatively.
Authors: Claudette E Loo; Marieke E Straver; Sjoerd Rodenhuis; Sara H Muller; Jelle Wesseling; Marie-Jeanne T F D Vrancken Peeters; Kenneth G A Gilhuijs Journal: J Clin Oncol Date: 2011-01-10 Impact factor: 44.544
Authors: Rita Nanda; Minetta C Liu; Christina Yau; Rebecca Shatsky; Lajos Pusztai; Anne Wallace; A Jo Chien; Andres Forero-Torres; Erin Ellis; Heather Han; Amy Clark; Kathy Albain; Judy C Boughey; Nora T Jaskowiak; Anthony Elias; Claudine Isaacs; Kathleen Kemmer; Teresa Helsten; Melanie Majure; Erica Stringer-Reasor; Catherine Parker; Marie C Lee; Tufia Haddad; Ronald N Cohen; Smita Asare; Amy Wilson; Gillian L Hirst; Ruby Singhrao; Katherine Steeg; Adam Asare; Jeffrey B Matthews; Scott Berry; Ashish Sanil; Richard Schwab; W Fraser Symmans; Laura van 't Veer; Douglas Yee; Angela DeMichele; Nola M Hylton; Michelle Melisko; Jane Perlmutter; Hope S Rugo; Donald A Berry; Laura J Esserman Journal: JAMA Oncol Date: 2020-05-01 Impact factor: 31.777
Authors: Laura S Dominici; Viviana M Negron Gonzalez; Aman U Buzdar; Anthony Lucci; Elizabeth A Mittendorf; Huong T Le-Petross; Gildy V Babiera; Funda Meric-Bernstam; Kelly K Hunt; Henry M Kuerer Journal: Cancer Date: 2010-06-15 Impact factor: 6.860
Authors: Judy C Boughey; Linda M McCall; Karla V Ballman; Elizabeth A Mittendorf; Gretchen M Ahrendt; Lee G Wilke; Bret Taback; A Marilyn Leitch; Teresa Flippo-Morton; Kelly K Hunt Journal: Ann Surg Date: 2014-10 Impact factor: 12.969
Authors: Priya Rastogi; Stewart J Anderson; Harry D Bear; Charles E Geyer; Morton S Kahlenberg; André Robidoux; Richard G Margolese; James L Hoehn; Victor G Vogel; Shaker R Dakhil; Deimante Tamkus; Karen M King; Eduardo R Pajon; Mary Johanna Wright; Jean Robert; Soonmyung Paik; Eleftherios P Mamounas; Norman Wolmark Journal: J Clin Oncol Date: 2008-02-10 Impact factor: 44.544